Meeting
2017 ASCO Annual Meeting
CD4+ T cells in PBMC to predict the outcome of anti-PD-1 therapy.
Authors
Hiroshi Kagamu
Niigata University, Niigata, Japan
Hiroshi Kagamu , Ou Yamaguchi , Ayako Shiono , Atsuto Mouri , Sachiko Miyauchi , Harue Utsugi , Fuyumi Nishihara , Takahiro Uchida , Yoshitake Murayama , Kunihiko Kobayashi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11525)
DOI
10.1200/JCO.2017.35.15_suppl.11525
Abstract #
11525
Poster Bd #
225
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Prognostic value of PD-L1+CD4+ T cells in non-small cell lung cancer (NSCLC) patients treated with a PD-1 inhibitor.
First Author: Kiriaki E. Vetsika
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2023 ASCO Genitourinary Cancers Symposium
Characterization of anti-cancer immune response associated with immune-related adverse events in patients with kidney cancer.
First Author: Taigo Kato
Poster
2022 ASCO Annual Meeting
Association of LAG-3 expression in circulating T cells and response to combination temozolomide (TMZ) and nivolumab (NIVO) in advanced neuroendocrine neoplasms (NENs): Results from an investigator-initiated phase 2 trial.
First Author: Vineeth Sukrithan